GoodmanADBrownTRKruppLBet al. Sustained-release oral fampridine in multiple sclerosis: A randomised, double-blind, controlled trial. Lancet2009; 373(9665): 732–738.
2.
GoodmanADBrownTREdwardsKRet al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol2010; 68(4): 494–502.
3.
PanicucciECohenMBourgVet al. De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. Mult Scler2019; 25: 618–621.
4.
Fampyra® (fampridine): Summary of Product Characteristics (SmPC), www.medicines.org.uk (accessed 20 August 2018).
5.
JaraMAquilinaTAupperlePet al. Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States. Drug Healthc Patient Saf2015; 7: 169–174.
6.
LundCNakkenKOEdlandAet al. Multiple sclerosis and seizures: Incidence and prevalence over 40 years. Acta Neurol Scand2014; 130(6): 368–373.
7.
GaspariniSFerlazzoEAscoliMet al. Risk factors for unprovoked epileptic seizures in multiple sclerosis: A systematic review and meta-analysis. Neurol Sci2017; 38(3): 399–406.
8.
de GusmaoCMOrtegaMRWallaceDM. Status epilepticus associated with dalfampridine in a patient with multiple sclerosis. J Neuropsychiatry Clin Neurosci2012; 24(4): E47–8.
